Israel and Waltham, Massachusetts-based Eloxx Pharmaceuticals Ltd, a developer of treatments that focus on genetic diseases caused by nonsense mutations, has raised $6 million in funding. The investors included Korea Investment Partners, DSC Investments, Dr. Phil Frost, OPKO Health Inc and Pontifax.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: